<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613181</url>
  </required_header>
  <id_info>
    <org_study_id>ANG1005-CLN-07</org_study_id>
    <nct_id>NCT03613181</nct_id>
  </id_info>
  <brief_title>ANG1005 in Leptomeningeal Disease From Breast Cancer</brief_title>
  <acronym>ANGLeD</acronym>
  <official_title>A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients With Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiochem Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiochem Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a
      Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed
      leptomeningeal disease and previously treated brain metastases.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization to experimental arm and comparator arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of randomization until death due to any cause, assessed for up to 2 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central nervous system progression-free survival</measure>
    <time_frame>From the date of randomization until central nervous system progression, assessed for up to 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central nervous system clinical benefit rate at 3, 6 and 12 months</measure>
    <time_frame>At 3, 6 and 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month and 12-month overall survival rates</measure>
    <time_frame>At 6 and 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptomeningeal carcinomatosis response rate</measure>
    <time_frame>Assessed for up to 2 years from first patient randomised.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of leptomeningeal carcinomatosis response</measure>
    <time_frame>Assessed for up to 2 years from first patient randomised.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in triple negative breast cancer patients</measure>
    <time_frame>From the date of randomization until death due to any cause, assessed for up to 2 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Leptomeningeal Carcinomatosis</condition>
  <condition>Leptomeningeal Metastases</condition>
  <condition>Brain Metastases</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ANG1005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANG1005 Investigational Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Best Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG1005</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>ANG1005</arm_group_label>
    <other_name>paclitaxel trevatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's Best Choice</intervention_name>
    <description>Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.</description>
    <arm_group_label>Physician's Best Choice</arm_group_label>
    <other_name>capecitabine</other_name>
    <other_name>eribulin</other_name>
    <other_name>high-dose IV methotrexate.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years old

          2. HER2-negative breast cancer

          3. At least 2 months of expected survival

          4. Newly diagnosed leptomeningeal carcinomatosis

          5. Documented history of brain metastasis that has been previously treated with radiation
             therapy

          6. Neurologically stable

          7. Eastern Cooperative Oncology Group performance status grade ≤2

          8. Adequate laboratory test results prior to first dose

          9. Patients who are fertile must agree to remain abstinent or use reliable method of
             birth control

        Exclusion Criteria:

          1. Any prior treatment for leptomeningeal carcinomatosis, except emergency radiotherapy
             or shunt

          2. Prior treatment with ANG1005

          3. Patients who have not had radiotherapy for their brain metastases

          4. Evidence of symptomatic intracranial hemorrhage or increased intracranial pressure

          5. Patients for whom intrathecal therapy is the most appropriate therapy for
             leptomeningeal disease

          6. Pregnancy or lactation and patients planning to be pregnant during the study

          7. Peripheral neuropathy &gt; Grade 2

          8. Evidence of severe or uncontrolled diseases

          9. Presence of an infection including abscess or fistulae, or known infection with
             hepatitis B or C or HIV

         10. History of interstitial lung disease

         11. Severe conduction disturbance

         12. Central nervous system disease requiring immediate neurosurgical intervention

         13. Known allergy to paclitaxel or any of its components

         14. Contra-indication for contrast-enhanced MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty Lawrence</last_name>
    <role>Study Director</role>
    <affiliation>Angiochem Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Nezvitsky</last_name>
    <phone>+1 514 788 7800</phone>
    <phone_ext>108</phone_ext>
    <email>lnezvitsky@angiochem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vihra Iordanova</last_name>
    <phone>+1 514 788 7800</phone>
    <phone_ext>106</phone_ext>
    <email>viordanova@angiochem.com</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANG1005</keyword>
  <keyword>Leptomeningeal carcinomatosis</keyword>
  <keyword>Leptomeningeal disease</keyword>
  <keyword>Leptomeningeal metastases</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

